Cyclacel Pharmaceuticals (NASDAQ:CYCC) Releases Quarterly Earnings Results, Beats Estimates By $0.11 EPS

Cyclacel Pharmaceuticals (NASDAQ:CYCC) released its quarterly earnings results on Wednesday. The biotechnology company reported ($0.72) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.11, Zacks reports. Cyclacel Pharmaceuticals had a negative return on equity of 1,009.04% and a negative net margin of 4,401.34%. During the same quarter in the previous year, the firm posted ($6.60) earnings per share.

Cyclacel Pharmaceuticals Trading Down 9.0 %

CYCC traded down $0.13 during mid-day trading on Thursday, hitting $1.32. 607,733 shares of the stock were exchanged, compared to its average volume of 428,706. The firm’s fifty day moving average is $1.63 and its two-hundred day moving average is $2.05. Cyclacel Pharmaceuticals has a 1-year low of $1.23 and a 1-year high of $11.34. The company has a market cap of $1.93 million, a PE ratio of -0.06 and a beta of 0.59.

Analyst Ratings Changes

A number of research analysts have commented on CYCC shares. Roth Mkm decreased their target price on shares of Cyclacel Pharmaceuticals from $21.00 to $11.00 and set a “buy” rating on the stock in a research report on Friday, May 3rd. StockNews.com lowered shares of Cyclacel Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, June 27th.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.